Peter Libby: Exploring Inflammation in Atherosclerosis: Lessons and Therapeutic Implications
Peter Libby, Mallinckrodt Professor of Medicine and Cardiovascular Specialist at Harvard Medical School and Brigham and Womens Hospital, shared a post on LinkedIn:
“Oliver Soehnlein led our update on inflammation in atherosclerosis and the opportunities for novel therapies to quench the smoldering within the plaque and improve clinical outcomes. Table 1 features “Emerging preclinical interference strategies aimed at reducing atherosclerosis” and Figure 5 presents a “Timeline of major milestones of research connecting inflammation with atherosclerosis” which we hope ongoing studies and clinical trials will soon extend as we seek the “sweet spot” of calming inflammation while avoiding undue interference with host defenses or tumor surveillance. Libby and Soehnlein, Inflammation in atherosclerosis: Lessons and therapeutic implications, Immunity (2025),”
Title: Inflammation in atherosclerosis: Lessons and therapeutic implications
Authors: Peter Libby, Oliver Soehnlein
Read full article here.
Stay updated with Hemostasis Today.
-
Apr 11, 2026, 13:51David McIntosh: Vital Plasma Derived Medicines – The Anomalous UK Scene
-
Apr 11, 2026, 13:47Samrawit Terefe: O Negative Blood Is the Universal Donor With Extreme Scarcity
-
Apr 11, 2026, 13:39Dheeraj Garg: Rethinking Cardiovascular Disease – A Cardiologist’s Perspective
-
Apr 11, 2026, 13:37Kushal Bhatia: Is The 4.5-Hour Thrombolysis Window Officially Outdated?
-
Apr 11, 2026, 13:35William Aird: Why Did Mammalian Red Blood Cells Give Up Their Nucleus?
-
Apr 11, 2026, 13:30Ken Kuang: Gravity Is Constant, But Your Vein Health Doesn’t Have to Be
-
Apr 11, 2026, 13:21Mascha Kern: Measuring Gender’s Role in Stroke and Migraine
-
Apr 11, 2026, 13:10Danique Steeghs: Key Findings from a Microfluidic Chemiluminescent Thrombin Generation Assay
-
Apr 11, 2026, 13:06Shanvi Mahi: A Validated Tool to Explore Lived Experiences After Stroke Rehabilitation